Want to see CLYM full AI Analyst Report?
Total Valuation
Climb Bio has a market cap or net worth of $798.94M. The enterprise value is $811.24.
Market Cap$798.94M
Enterprise Value$811.24
Share Statistics
Climb Bio has 57,436,256 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding57,436,256
Owned by Insiders20.10%
Owned by Institutions54.37%
Financial Efficiency
Climb Bio’s return on equity (ROE) is -0.37 and return on invested capital (ROIC) is -42.16%.
Return on Equity (ROE)-0.37
Return on Assets (ROA)-0.36
Return on Invested Capital (ROIC)-42.16%
Return on Capital Employed (ROCE)-0.42
Revenue Per Employee0.00
Profits Per Employee-2.14M
Employee Count28
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Climb Bio is ―. Climb Bio’s PEG ratio is 0.11.
PE Ratio―
PS Ratio0.00
PB Ratio1.69
Price to Fair Value1.69
Price to FCF-4.97
Price to Operating Cash Flow-20.39
PEG Ratio0.11
Income Statement
In the last 12 months, Climb Bio had revenue of 0.00 and earned -59.85M in profits. Earnings per share was -0.88.
Revenue0.00
Gross Profit-97.00K
Operating Income-67.88M
Pretax Income-59.85M
Net Income-59.85M
EBITDA-59.75M
Earnings Per Share (EPS)-0.88
Cash Flow
In the last 12 months, operating cash flow was -52.70M and capital expenditures -369.00K, giving a free cash flow of -53.07M billion.
Operating Cash Flow-52.70M
Free Cash Flow-53.07M
Free Cash Flow per Share-0.92
Dividends & Yields
Climb Bio pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.69
52-Week Price Change565.57%
50-Day Moving Average14.24
200-Day Moving Average9.16
Relative Strength Index (RSI)45.53
Average Volume (3m)1.43M
Important Dates
Climb Bio upcoming earnings date is Nov 11, 2026, Before Open (Confirmed).
Last Earnings DateAug 6, 2026
Next Earnings DateNov 11, 2026
Ex-Dividend Date―
Financial Position
Climb Bio as a current ratio of 15.16, with Debt / Equity ratio of 0.55%
Current Ratio15.16
Quick Ratio15.16
Debt to Market Cap<0.01
Net Debt to EBITDA0.59
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Climb Bio has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Climb Bio EV to EBITDA ratio is -3.95, with an EV/FCF ratio of -4.33.
EV to Sales0.00
EV to EBITDA-3.95
EV to Free Cash Flow-4.33
EV to Operating Cash Flow-4.34
Balance Sheet
Climb Bio has $183.12M in cash and marketable securities with $1.31M in debt, giving a net cash position of $181.81M billion.
Cash & Marketable Securities$183.12M
Total Debt$1.31M
Net Cash$181.81M
Net Cash Per Share$3.17
Tangible Book Value Per Share$2.37
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Climb Bio is $28.11, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$28.11
Price Target Upside74.82% Upside
Analyst ConsensusStrong Buy
Analyst Count12
Revenue Growth Forecast―
EPS Growth Forecast-19.29%